JAPAN does not forgive generic strategy.
De-risk your multimillion-dollar market entry with the only clinician-led commercial architecture firm in Japan/APAC.
Clinical Execution • Market Access • Commercial Readiness • Leadership Acquisition
the silent failure of healthcare expansion
Global innovators don't fail in Japan because their technology is bad. They fail because they treat Japan as "just another territory."
The Talent Gap: You hire a "safe" Country Manager who manages the status quo but cannot scale.
The Clinical Disconnect: You have the regulatory approval, but the KOLs aren't prescribing.
The Commercial Plateau: Your distributor is collecting a margin while your brand equity rots.
The Verdict: If you do not have Clinical Credibility aligned with Commercial Aggression, you are not investing—you are donating.
clinician-led. commercially proven.
We operate at the intersection of Clinical Execution, Market Access, Commercial Readiness, and Leadership Acquisition.
Founded by Emilio Campos, D.D.S.: Strategy that speaks the language of your customers (Clinicians).
28+ Years Ecosystem Depth: Deep networks in Japan & APAC.
Full-Stack Execution: From Genomics, Oncology & Rare Disease, MedTech to Digital Health & Medical Aesthetics.
Proven Speed: We deliver actionable 1-page war plans, not 100-page academic novels.
the 3-pillar growth engine
STRATEGIC TALENT
The Foundation
We don't just fill seats. We engineer the leadership team necessary to execute the P&L.
Delivers: Organizational Design, Capability Architecture, Human Capital Risk De-Risking.
CLINICAL EXECUTION
The MoatLeverage an independent ecosystem intelligence layer to align local evidence generation, PMDA/MHLW regulatory positioning, and investigator networks.
Delivers: KOL mapping, Launch readiness, Investigator networks, Clinical adoption strategy, Market access alignment.
COMMERCIAL TRACTION
The Revenue
Navigate the distributor vs. direct maze and break through revenue plateaus.
Delivers: Launch Playbooks, Turnaround Audits, Distribution Channel Strategy.
deployment architecture
We reject hourly billing. we engage via defined outcomes or retained access.
FOCUSED SPRINT
For: Market Entrants & Scalers requiring a specific commercial unlock.
The Deliverable: A defined, 90-day tactical engagement to execute one of our Core Pillars (Clinical, Commercial or Talent).
Scope: Fixed & Finite.
Velocity: High-Speed Execution.
Outcome: 1-Page Playbook + Key Hires/KOLs Secured.
Ideal For:
Building the initial Launch Team.
Mapping & Engaging the first 10 KOLs.
Auditing a failing Distributor channel.
RETAINED ADVISORY
(Limited Capacity: 2 Seats Available)
For: Founders and P&L Owners who need on-demand strategic air cover without the operational drag of a full consulting engagement.
The Access:
Fractional Japan Market Entry & Clinical Execution Partner
For companies that:
are entering Japan
are rebuilding Japan
are launching a strategic asset
need executive-level guidance without building a full local infrastructure
Ideal For:
De-risking investor updates & board strategy.
Sanity-checking local team performance.
Navigating complex regulatory/clinical pivots.
trusted by the p&L owners of:
Dental, Regen Med, Med Aesthetics
Straumann
Nobel Biocare
Dentsply Sirona
Align Technology
Geistlich Pharma
ZO Skin Health
Establishment Labs
Miltenyi Biotec
Sony Biotechnology
Leica Biosystems
Kimberly Clark HC
What Our Partners Are Saying…
"Re-entering Japan after a difficult distributor partnership felt like starting from zero. We had no team and a stalled growth trajectory in our second-largest market. Inoventic didn't just find candidates; they served as our strategic partner, building our entire commercial and operational team from the ground up. They understood our uniquely complex talent needs and delivered the 10 leaders who turned our business around, allowing us to hit our ambitious scale-up targets."
— SVP, Global Medical Aesthetics Company
Scientific & Diagnostics
Illumina
PacBio
Sebia
Thermo Fisher Scientific
Bio-Rad Laboratories
Qiagen
Beckman Coulter
Sysmex
Hologic
Bruker
AB Sciex
Nova Biomedical
Mettler Toledo
Broader MedTech & Pharma Ecosystem
Merck
UCB
Teva
Takeda Pharma
LONZA
Almac
Covance
EPS
Hitachi Hi-Tech
IDEXX Laboratories
Eurofins Genomics
FOSS
Catalent
A.D.A.M. Innovations
"We chose Japan as the global launchpad for our game-changing new technology, which came with immense investor pressure and zero room for error. The standard commercial profile wasn't a fit for our sensitive category. Inoventic understood this perfectly and secured the two foundational leaders—our APAC Head of Medical Education and Brand Manager—who were instrumental in our success. Their work directly contributed to a successful clinical launch, positive KOL engagement, and a significant increase in our stock price."
— CEO, US-Based FemTech Innovator
"We were at a critical inflection point, facing immense investor pressure to transform our consumer genomics company into a regional, AI-driven data platform for a potential IPO. This required a complete overhaul of our leadership and culture. Inoventic was the strategic partner who architected our new executive dream team. They brought us the A-list leaders—our new CMO, CTO, CSO, and Heads of Comms and PR from companies like Google and Mercari—who laid the foundation to transform our business model and position us as the undisputed leader in our market."
— Board Member, APAC-based Genomics AI Company
